神经生长因子联合盐酸多奈哌齐治疗帕金森病临床疗效及作用机制分析

目的：分析神经生长因子联合盐酸多奈齐治疗帕金森病临床疗效及对血清炎性因子及脑神经递质的影响。方法：收集104例帕金森病患者作为观察对象，随机分为对照组和观察组，每组各52例。对照组给予盐酸多奈哌齐胶囊，观察组给予神经生长因子联合盐酸多奈哌齐胶囊治疗。治疗3个月后，比较2组血清炎性因子、脑神经递质、临床疗效、不良反应。结果：观察组有效率88.46%明显高于对照组73.08%（χ²=3.962，P<0.05）；血清白细胞介素-6（IL-6）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）含量明显低于对照组（t=6.722，10.246，4.090，P<0.05，P<0.01）；脑神经递质多巴胺（DA）、去甲肾上腺素（NE）、5羟色胺（5-HT）明显高于对照组（t=10.162，7.887，3.884，P<0.05，P<0.05，P<0.01）；2组不良反应比较无统计学差异（11.54% vs 7.69%）（χ²=0.443，P>0.05）。结论：神经生长因子联合盐酸多奈齐有助于提高帕金森病患者临床疗效，可能与抑制炎症状态、调节脑神经递质等因素有关。

Effects of nerve growth factor combined with donepezil hydrochloride on serum inflammatory factors and brain neurotransmitters in patients with Parkinson's disease and possible analysis of mechanism

OBJECTIVE To investigate the clinical efficacy of nerve growth factor (NGF) combined with donazil hydrochloride on serum inflammatory factors and brain neurotransmitters in patients with Parkinson's disease. METHODS 104 patients with Parkinson's disease were randomly divided into control group and observation group, with 52 cases in each group. The control group was given donepezil hydrochloride capsule, while the observation group was given nerve growth factor combined with donepezil hydrochloride capsule. After 3 months of treatment, the serum inflammatory factors, brain neurotransmitters, clinical efficacy and adverse reactions were compared between the two groups. RESULTS The effective rate of the observation group was 88.46%, which was significantly higher than that of the control group (73.08%, χ²=3.962, P<0.05); serum levels of interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-alpha) were significantly lower than those in the control group(t=6.722, 10.246, 4.090, P<0.05, P<0.01); Brain neurotransmitters dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT) were significantly higher than those in the control group(t=10.162, 7.887, 3.884, P<0.05, P<0.05, P<0.01); There was no significant difference in adverse reactions between the two groups(11.54% vs 7.69%, χ²=0.443, P>0.05). CONCLUSION Nerve growth factor combined with donezil hydrochloride can improve the clinical efficacy of patients with Parkinson's disease, which may be related to the inhibition of inflammation, regulation of brain neurotransmitters and other factors.